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RESEARCH ARTICLE
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Abstract
Introduction: Diversity in cognition among apolipoprotein E (APOE) ε4 homozygotes
can range from early-onset Alzheimer’s disease (AD) to a lifetime with no symptoms.
Methods: We evaluated a phenotypic extreme polygenic risk score (PRS) for AD
between cognitively healthy APOE ε4 homozygotes aged ≥75 years (n = 213) and earlyonset APOE ε4 homozygote AD cases aged ≤65 years (n = 223) as an explanation for
this diversity.
Results: The PRS for AD was significantly higher in APOE ε4 homozygote AD cases
compared to older cognitively healthy APOE ε4/ε4 controls (odds ratio [OR] 8.39; confidence interval [CI] 2.0–35.2; P = .003). The difference in the same PRS between APOE
ε3/ε3 extremes was not as significant (OR 3.13; CI 0.98–9.92; P = .053) despite similar
numbers and power. There was no statistical difference in an educational attainment
PRS between these age extreme case-controls.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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Discussion: A PRS for AD contributes to modified cognitive expression of the APOE
ε4/ε4 genotype at phenotypic extremes of risk.
KEYWORDS

Alzheimer’s disease, Alzheimer’s disease dementia, apolipoprotein E, dementia resilience, genetic
modifiers, polygenic risk score

1

BACKGROUND

older APOE ε4/ε4 controls without a diagnosis of AD aged ≥ 75 years
(n = 213).

Alzheimer’s

disease

(AD)

has

a

strong

underlying

genetic

Cases came from the Alzheimer’s Disease Genetics Consortium

component.1–3 However, in the majority of individuals with non-

(ADGC) (n = 200) and The Australian Imaging, Biomarkers & Lifestyle

Mendelian AD, no single gene mutation can be identified as causative,

Flagship Study of Ageing (AIBL; n = 23). Diagnosis of probable AD

with studies showing that AD is either an oligogenic or a polygenic

in the cases was made using the Diagnostic and Statistical Manual of

disease.4–6 The apolipoprotein E (APOE) ε4 allele has been identified

Mental Disorders (DSM-IV) or the National Institute of Neurological

as the single biggest risk factor.7 The presence of APOE ε4 in the

and Communicative Disorders and Stroke– Alzheimer’s Disease and

heterozygous form confers a 2- to 3-fold increase in the odds of devel-

Related Disorders Association (NINDS-ADRDA) criteria or based on

oping AD and in the homozygous form this confers up to a 14.9-fold

detailed clinical assessment in individual cohorts. Further details of

ε3/ε3.8

these cohorts can be found in supporting information, the National

Moreover, the presence of APOE ε4 accelerates the age of onset (AOO)

Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site

of AD, with the mean AOO being 84.3 years in non-carriers as opposed

(NIAGADS; https://www.niagads.org/home), Kunkle et al.,18 and Ellis

to 68.4 years in those who are APOE ε4/ε4.9

et al.25

increase compared to the most common APOE genotype of

Despite the high risk for AD, it has been recognized that there is

Cognitively healthy older APOE ε4/ε4 controls without a diagnosis of

considerable phenotypic diversity among APOE ε4 homozygotes, rang-

AD were from the Aspirin in Reducing Events in the Elderly (ASPREE)

ing from early-onset AD to a lifetime with no symptoms of cogni-

study26 (n = 175), AIBL (n = 12), and ADGC (n = 26). ASPREE par-

tive impairment.10–13 The reasons for this phenotypic diversity remain

ticipants in this group had no clinical diagnosis of AD as determined

largely unexplained. Due to this variability in risk, APOE ε4 genotype,

by a multidisciplinary adjudicating committee and passed a test of

even in the homozygous state, has not demonstrated reliable utility

global cognition (Modified Mini-Mental State Examination [3MS] score

for individual prediction of AD susceptibility or AOO of AD.14,15 As

of > 77) at enrolment. Control participants from AIBL had no clini-

there is a large polygenic component to AD, genetic factors beyond

cal AD or mild cognitive impairment also determined by a multidis-

the APOE ε4 genotype may account for some of this modification in

ciplinary adjudicating committee. Controls with no reported clinical

risk. Using data from large AD-related genome-wide association stud-

AD were also included from ADGC, in which individual cohorts used

ies (GWAS),16–18 polygenic risk scores (PRS) have been developed and

specifically designed cognitive screening criteria to determine “non

used to predict risk for AD.6,16,19–24 However, to our knowledge, no

demented” status (https://www.niagads.org/home). Any ADGC sample

study has been designed specifically to examine the modification of risk

that was included in IGAP stage 1 or IGAP stage 2 in the GWAS by Lam-

by a PRS for AD between phenotypic extremes of the APOE ε4/ε4 risk

bert et al.16 was excluded, to remove overlap with current PRS anal-

spectrum. In this study, we investigate the role of an AD PRS, excluding

ysis. Demographic characteristics of cases and controls are shown in

the APOE region, as a potential modifier of risk between the two phe-

Table 1.

notypic extreme ends of the APOE ε4/ε4 AD risk spectrum, comparing

Matched numbers of APOE ε3/ε3 AD cases (n = 223) with AOO ≤ 65

the PRS between cognitively healthy older APOE ε4/ε4 controls with-

years and APOE ε3/ε3 cognitively healthy controls (n = 213) without AD

out AD and APOE ε4/ε4 early-onset clinically diagnosed AD cases.

aged ≥ 75 years were also included to compare the effect of the PRS
in APOE ε3/ε3 extremes. Cases and controls for the APOE ε3/ε3 comparison were European ancestry participants, sourced from ADGC. As

2

METHODS

APOE ε3 is the most common genotype in the general population, this
genotype was chosen for the comparison analysis.27

2.1

Participants

This study was approved by the Royal Melbourne Hospital Ethics
Committee (HREC/17/MH/444) for use of pre-collected data. Eth-

To compare a PRS for AD between the phenotypic extreme of the APOE

ical approval for the individual cohort participants was provided

ε4/ε4 risk spectrum, we obtained young onset AD cases and cogni-

by their respective institutional ethics boards. All participants had

tively healthy older controls of European origin with APOE ε4/ε4 geno-

provided DNA samples to the respective cohorts with consent for

type from various cohorts. This included genotype data from APOE

genotyping and data use. All patient data was anonymized prior

ε4/ε4 AD cases with AOO ≤ 65 years (n = 223) and cognitively healthy

to analysis. The reporting of this study follows the Strengthening
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the Reporting of Observational studies in Epidemiology (STROBE)
guidelines for case-control studies (https://www.strobe-statement.
org/index.php?id = strobe-home).

RESEARCH IN CONTEXT
1. Systematic review: Despite the high risk for Alzheimer’s
disease (AD), there is considerable diversity in cognition

2.2

Generating AD PRS in phenotypic extremes

among apolipoprotein E (APOE) ε4 homozygotes, ranging
from early-onset AD to a lifetime with no dementia. Literature review (PubMed) revealed that the reasons for this

A phenotypic extremes study design was used to select cases and controls for this study.28,29 Study design is depicted in Figure 1.

phenotypic diversity remain largely unexplained. In this
study, we investigated the effect of a polygenic risk score

Detailed information on genotyping and quality control (QC) steps
is included in supporting information. To mitigate the amount of technical variability introduced by combining samples from multiple cohorts,
only samples that passed QC filters based on sex, relatedness, and
European ancestry were included. Principal component analysis (PCA)
on the top 10 principal components (PC) was done in each cohort to
exclude outliers. Variants with call rates < 95% and those likely to
have been improperly genotyped or imputed based on a test of HardyWeinberg equilibrium were excluded. QC was repeated after merging
the cohorts and PCA was again performed to control for population
stratification.

(PRS) in this modification.
2. Interpretation: Using an extremes phenotype study
model, we demonstrate that a PRS for AD contributes to
modified cognitive expression of the APOE ε4/ε4 genotype.
3. Future directions: This study demonstrates an effective
framework for investigation of risk modifiers in AD. A
similar model can be used to investigate other AD risk
modifiers. Conducting genome-wide association studies
using this framework, with larger participant numbers,
may lead to discovery of novel risk-modifying loci. Inclu-

PRS is calculated as a single score generated by aggregating the
effects of genetic variants across the genome relevant for that particular trait.30 As there is no published PRS available for a pheno-

sion of AD risk modifiers along with APOE genotyping will
aid in more accurate AD risk prediction.

typic and age extreme AD dataset of homozygous APOE genotypes, we
undertook a clumping and thresholding method (described in supporting information) to generate a PRS in our age and phenotypic extreme
APOE ε4/ε4 and APOE ε3/ε3 samples.

The phenotypic extreme APOE ε4/ε4 as well as APOE ε3/ε3 participants (total cases n = 446; total controls n = 426) were combined

Clumping and thresholding is a common method used to compute

to generate the PRS. To calculate PRS without APOE, variants within

PRS. Single nucleotide polymorphisms (SNPs) are first selected from

750 kilobases of the start or end of the APOE gene (chr19:44659011-

GWAS summary statistics. The clumping step ensures that only vari-

46162650, hg19) were excluded. Effect sizes for the weighting of the

ants that are weakly correlated with one another are retained in a pre-

SNPs used for the PRS generation was from the GWAS analysis by Lam-

specified window of the genome (in this case 1000 kilobase windows).

bert et al.16 The more recent GWAS by Kunkle et al. was not used as the

Then the thresholding step is used to remove variants with a P-value

ADGC samples in this study overlap with their GWAS study.18 The soft-

larger than a chosen level of significance (in this study, SNPs from the

ware PRSice-2 was used to calculate and optimize PRS using clump-

IGAP GWAS were threshold at r2 > 0.1). Only the most significant P-

ing and thresholding.31,32 The steps followed in the PRS generation are

value threshold was used to select the SNPs that form the PRS.

shown in Figure 1.

TA B L E 1

Demographic characteristics of APOE ε4/ε4 and APOE ε3/ε3 participants

Characteristics

Young onset AD
cases with APOE
ε4/ε4

Cognitively
healthy older
controls with
APOE ε4/ε4

Young onset cases
with APOE ε3/ε3

Cognitively healthy older
controls with APOE ε3/ε3

Total numbers

223

213

223

213

ASPREE

0

175

0

0

AIBL

23

12

0

0

Numbers by cohort:

200

26

223

213

Median AOO/AAA
(range) in years

ADGC

62.5 (47–65)

80.5 (75–91)

57 (34–64)

83 (76–97)

Female sex

53.8%

52.6%

53.4%

62.9%

Abbreviations: AAA, age at assessment; AD, Alzheimer’s disease; ADGC, Alzheimer’s Disease Genetics Consortium; AIBL, The Australian Imaging, Biomarkers
& Lifestyle Flagship Study of Ageing; AOO, age of onset; ASPREE, Aspirin in Reducing Events in the Elderly; APOE, apolipoprotein E.
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F I G U R E 1 Flow-chart detailing the study design. AAA, Age at assessment; ADGC, Alzheimer’s Disease Genetics Consortium; AIBL, The
Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing; AOO, age of onset; ASPREE, Aspirin in Reducing Events in the Elderly study;
IGAP, International Genomics of Alzheimer’s Project; OR, odds ratio; PC, principal components; PRS, polygenic risk score; QC, quality control.
Summary statistics for IGAP stage 1 and 2 samples derived from Lambert et al.16 Principal component analysis (PCA) was done using first ten PCs
based on the 1000 Genomes reference population

2.3

Statistical analysis

Using the PRS thus generated, the means of PRS distributions between

3

RESULTS

Out of a total of 5,295,512 SNPs that passed QC in the combined

the age extreme APOE ε4/ε4 cases and APOE ε4/ε4 controls were first

APOE ε4/ε4 and APOE ε3/ε3 age-extreme samples, after excluding SNPs

analyzed using the statistical test analysis of covariance (with 10 PCs

at a minor allele frequency (MAF) < 0.05 and clumping, 33,780 SNPs

as covariates) and post hoc t test. This was done to check that there was

remained. These SNPs were then subjected to P-value thresholding.

significant difference in PRS between the cases and controls in each

Figure 2 shows the results of the clumping and thresholding process.

group before calculating odds ratios (OR). Subsequently, OR were cal-

The r2 explained by PRS was calculated at IGAP GWAS P-values from

culated between the lowest and highest 20% of PRS (OR_20%) by per-

5 × 10–08 to 1. There were 21 SNPs that fell in the most significant

forming logistic regressions between PRS quintile and AD status, in the

threshold, with the corresponding P-value bracket being P < 5 × 10–08 .

APOE ε4/ε4 case-controls, and also in the APOE ε3/ε3 case-controls. OR

This P-value happened to correspond to the P-value universally used to

were also calculated per standard deviation increase in PRS (OR_Stnd)

select the most significant SNPs in GWAS studies, that is, at genome-

by performing logistic regressions with Z-standardized PRS as the pre-

wide significance level. Details of these SNPs are provided in Table S1

dictor and AD status as the response. Level of significance was set at

in supporting information.

P < .05.

The difference in means between the extreme cases and controls

To verify if the variation in PRS was influenced by differences in

was significant in both the APOE ε4/ε4 case-controls (P < .001) and the

other AD-related risk factors in the APOE ε4/ε4 phenotypic extremes,

APOE ε3/ε3 case-controls (P < .001) showing that the participants with

we intended to check for differences in educational attainment

AD have a significantly higher PRS compared to controls (Figure 3).

between the cases and controls. Of the various modifiable risk factors,

The OR_20% in APOE ε4/ε4 extremes was 8.39 (confidence interval [CI]

low level of education is the only trait to exhibit consistent association

2.0–35.2; P = .003), indicating a significant depletion of high risk PRS

Large GWAS studies have shown that genetically predicted

SNPs in the cognitively healthy older controls with APOE ε4/ε4. We also

education correlates with actual level of education and that high edu-

calculated the OR per standard deviation for the entire distribution of

with AD.33

cation attainment PRS is protective against AD.34 As level of education

the APOE ε4/ε4 extreme cases and controls. OR_Stnd was 1.58 (CI 1.1–

was not available as a variable across the different cohorts included

2.3; P = .013; Figure 4).

in our study, we calculated an education attainment PRS based on the

As APOE ε3/ε3 is the most common genotype in the general popula-

GWAS study by Lee et al.35 as a proxy for level of education in the APOE

tion and considered the population reference, analysis in participants

ε4/ε4 extremes. To generate the education attainment PRS, we applied

with this genotype was used as a comparison to determine whether

clumping and thresholding to the Lee et al. GWAS using the same meth-

there is a modifying effect of the PRS in APOE ε4-negative phenotypic

ods as described above for AD. The statistical package R (version 3.6.2)

extremes. OR between the highest and lowest 20th percentile, that is,

was used for statistical analysis and figures.36

OR_20% was 3.13 (CI 0.98–9.92; P = .053), showing a relatively lower
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F I G U R E 2 Line plot depicting the thresholding of single nucleotide polymorphisms. Each dot represents a different thresholding window. Best
threshold in this case was at P < 5 × 10–08

F I G U R E 3 Density plot showing the difference in polygenic risk score distribution in cases and controls in the apolipoprotein E (APOE) ε4/ε4
extremes and APOE ε3/ε3 extremes
influence of this modifying PRS in the APOE ε3/ε3 phenotypic extremes,

cation attainment was not confounding. Similarly, there was no statis-

as opposed to the APOE ε4/ε4 phenotypic extremes at the two extreme

tically significant difference in the education attainment PRS between

quintile ends of the PRS distribution. OR_Stnd was 1.36 (CI 0.99–1.85;

the APOE ε3/ε3 extreme cases and controls with OR_20% being 3.12

P = .054; Figure 4).
To clarify if the risk modification conferred by the PRS in APOE

(CI 0.98–9.92; P = .05) and OR_Stnd being 0.70 (CI 0.42–1.14; P = .15;
Figure 4).

ε4/ε4s may have been influenced by a difference in education attainment, we checked for differences in genetically determined education
attainment between the APOE ε4/ε4 cases and controls as well as the

4

DISCUSSION

APOE ε3/ε3 cases and controls. The education attainment PRS was
more polygenic with 24,502 SNPs falling under the most significant

In this study, we compared a PRS between phenotypic extremes of the

threshold of P = .3. The education attainment PRS was not significantly

APOE ε4/ε4 spectrum and demonstrated that the PRS was significantly

different between the APOE ε4/ε4 extreme cases and controls with

higher in APOE ε4 homozygotes diagnosed with AD earlier in life,

OR_20% 0.52 (CI 0.17–1.60; P = .26) and OR_Stnd 0.83 (CI 0.6–1.16;

compared to APOE ε4 homozygotes who remained unaffected by AD

P = .28), indicating that the influence of genetically determined edu-

to an advanced age. The PRS was also compared between a matched
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F I G U R E 4 Odds ratio of risk-modifying polygenic risk score (PRS) as well as education attainment PRS in apolipoprotein E (APOE) ε4/ε4
extremes and APOE ε3/ε3 extremes. CI, confidence interval; OR, odds ratio

number of APOE ε3/ε3 young onset cases and unaffected controls, but

burden of some non-APOE SNPs in APOE ε4 homozygotes could buffer

was not as significant as the APOE ε4/ε4 case-controls. Our findings

disease risk and delay AD onset to ≥ 75 years.

illustrate how genetic risk modification in AD can be driven by com-

An improved understanding of the modifying effect of PRS on the

mon AD-associated variants beyond the APOE locus, and that this risk

APOE ε4/ε4 genotype could assist in increasing the accuracy of risk

modification may partially explain the phenotypic diversity among

prediction for AD. Similar risk modification by PRS has been shown

APOE ε4 homozygotes.

recently in the context of autosomal dominant adult-onset mono-

Our extreme phenotyping study design increased the ability to

genic conditions, in which polygenic factors have been shown to mod-

detect this PRS modifying effect. Extreme phenotyping is known to

ify the penetrance of clinically significant monogenic variants.40 Such

increase statistical power and variant effect sizes, enabling better iden-

improved risk stratification is useful in identifying people at increased

tification of SNPs strongly associated with a trait.28 For AD, an extreme

risk or at decreased risk despite their APOE ε4/ε4 genotype.

phenotyping study translates to comparing risk factors between those

In the clinical setting, the APOE genotype has posed several chal-

at the highest risk, that is, AD cases with APOE ε4/ε4 and onset ≤ 65

lenges. The variability in AD phenotype despite the high risk has meant

years, with those who are most resilient to AD, being those with APOE

that testing for the APOE ε4 genotype has been discouraged by the

ε4/ε4 genotype, aged ≥ 75 years and no AD.37 Here, we have identified

American College of Medical Genetics and Genomics, especially in the

a PRS that modifies risk between the phenotypic extreme ends of the

predictive context in asymptomatic individuals.41 Addition of PRS to

APOE ε4/ε4 spectrum. This finding has important implications for the

the APOE ε4/ε4 genotyping increases the predictive value of such test-

potential risk stratification of this high-risk genotype.

ing and may allow the incorporation of APOE ε4/ε4 testing in the clinic,

The loci that yielded the 21 SNPs forming risk-modifying PRS in

where more accurate prediction of the chances of developing AD is

this study have all been previously described in AD GWAS with no

considered useful. It will also become more relevant as effective thera-

new loci found in this study. This shows that the currently known non-

pies for AD are developed.

APOE loci still play an important role in risk modification. Thus far,

Although phenotypic variability may also be true for the heterozy-

up to 44 loci have been reported to be associated with AD in large

gous APOE ε4 genotype, given that the elevated OR of developing late-

GWAS.5,16–18,38,39 However, it remains unresolved if AD is oligogenic,

onset AD in APOE ε4 homozygotes (up to 14.9) is markedly different

with risk determined by a smaller number of SNPs compared to other

from having one APOE ε4 allele (up to 4), the factors that modify the risk

common diseases such as coronary artery disease and cancer; or is

in APOE ε4 heterozygotes will be much broader, possibly with smaller

polygenic with similar genetic architecture to these diseases.5,6 The

effect sizes compared to those modifying APOE ε4/ε4 risk.8 The pre-

present analysis has demonstrated that a detectable risk-modifying

dictive value for AD by inclusion of a modifying PRS in addition to

effect in APOE ε4/ε4 extremes is driven by a relatively small number of

APOE ε4/ε4 genotyping would be significantly higher than the predic-

SNPs in the common frequency range. Our study showed that a lower

tive value of adding a modifying PRS to APOE ε4 heterozygotes. The
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APOE ε4/ε4 modifying PRS, especially in the extremes of phenotypes

ing individuals at either end of the APOE ε4/ε4 risk spectrum is par-

as described in this study, is therefore valuable in selecting appropri-

ticularly challenging given that the population genotype frequency of

ate participants for study of risk and resilience and will also contribute

APOE ε4/ε4 in Europeans is only 2%. This necessitated combining sam-

toward a better understanding of the genetic and non-genetic factors

ples from multiple cohorts in our analysis, which may have introduced

underpinning AD and how they interact.

some technical variation between cohorts and issues related to popu-

We were able to successfully incorporate an extreme pheno-

lation stratification. We have tried to account for this by various QC

type design to identify the modifying PRS by using well-phenotyped,

checks and PCA, but acknowledge that despite this, there may be dis-

resilient older controls in our study. Resilient controls are defined as

similarities between the cohorts.

those that do not develop a particular condition, despite being at a high

Moreover, risk prediction for AD remains complicated due to the

risk for developing it. As the average age of onset of AD in APOE ε4

complex genetic–environmental interactions and likely involvement of

homozygotes is 68.4 years,9 those who have the APOE ε4/ε4 genotype

epigenetic mechanisms. We acknowledge that despite having small

and are aged at least 75 years or older without major cognitive impair-

effect sizes individually, in combination, many lifestyle/environmental

ments, can be considered to be harboring factors that buffer the devel-

factors may play a larger part in modifying AD risk and this effect could

opment of AD, despite their high risk. In some previous AD case-control

not be accounted for in the present study.48

studies, participants too young be considered controls for AD have

There may also be other rare, high-effect genetic variants influenc-

been used.42–44 This confounds the ability to accurately determine

ing risk or resilience that have not been captured by our analysis. In

risk-modifying factors, as many of the controls may go on to develop

addition, our analysis does not cover genomic structural variants such

AD when older. In the current study, we had access to well-phenotyped,

as deletions, duplications, and short tandem repeats that may con-

advanced aged elderly control cohorts of APOE ε4/ε4 participants, who

tribute toward modification of AD risk. It is also to be noted that this

fit the definition of resilience for AD. Using appropriately phenotyped

PRS is not transferable to the non-White population as our study pop-

extreme cases and controls strengthens the ability to find meaningful

ulation was predominantly of European White ethnicity.

modifying factors.
Although many lifestyle and environmental factors can also play a
part in the modification of risk of AD, no single environmental/lifestyle

5

CONCLUSIONS

risk factor has been shown to be strongly associated with AD.33 A
recent study analyzing causal associations between various modifi-

In conclusion, our study demonstrates that a PRS for AD modifies the

able risk factors and the AD phenome, using PRS and Mendelian ran-

phenotypic expression of AD between extreme ends of the APOE ε4/ε4

domization, showed only genetically determined education attainment

risk spectrum. This suggests that common genetic variants beyond the

was causally associated with decreased risk of AD, delayed AOO, and

APOE locus contribute to risk modification in AD, yet it is likely that far

increased cortical surface area and thickness.45 Studies have shown

more genetic and non-genetic factors contribute, beyond those cap-

that the effect of education is particularly prominent in early years and

tured by the PRS. Further studies are required to better understand

that the effect of education is difficult to separate out from overall cog-

the underlying biology of genetic risk modifiers in AD. Although not

nitive ability.46,47 In a large GWAS study, Lee et al. were able to show

available in all our study cohorts, positron emission tomography or

that the SNPs associated with education attainment explained a signif-

cerebrospinal fluid biomarkers of amyloid beta (Aβ) should be explored

icant proportion of educational variance.35 We were also able to show

in the resilient controls in future studies to investigate if the non-

that the difference in the APOE ε4/ε4 modifying PRS was not influenced

amyloidogenic loci represented by the 21 SNPs described here counter

by the difference in education attainment PRS.

the effects of Aβ in the brain.
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